Protalex — Investor Presentation (September 2014)
18 slides from Protalex's investor presentation, Sep 5, 2014
Slide 1: September, 2014
September, 2014
Slide 2: Forward-Looking Statement
Protalex , Inc. Forward - Looking Statement Statements made in this presentation stating the Company ’ s beliefs, intentions, and expectations are forward - looking statements. The company ’ s actual results could differ materially from those projected. Additional information is contained in the com
Slide 3: Protalex, Inc. (Ticker: PRTX)
Protalex , Inc . (Ticker: PRTX) Biotechnology company developing a new class of drugs with the potential to revolutionize the treatment of autoimmune diseases Lead product: PRTX - 100 ▪ Highly purified formulation of Staphylococcal protein A, a natural protein isolated from cultured bacteria ▪ S
Slide 4: Lead Product, Market Opportunity, Company Structure
Protalex , Inc. Protalex , Inc. 4 Lead Product PRTX - 100 Market Opportunity Company Structure ▪ Rheumatoid Arthritis (>$18B) ▪ ITP (~$1B) ▪ Other Autoimmune Diseases ($Bs) ▪ Experienced Management ▪ Strong Scientific Advisors ▪ Low - burn Model ▪ Funded - to - date by majority shareholder ▪ Proprie
Slide 5: Investment Thesis
Protalex , Inc. Protalex Investment Thesis PRTX - 100 is a novel immunomodulatory biological with potential to be a blockbuster drug in various autoimmune diseases ▪ ITP — an orphan disease ▪ Rheumatoid arthritis — the largest autoimmune market To date, 5 clinical studies conducted demonstrate t
Slide 6: Animal Studies of PRTX-100
Protalex , Inc. Animal Studies of PRTX - 100 PRTX - 100 reduces footpad swelling in the murine CIA model of arthritis PRTX - 100 inhibits platelet phagocytosis by human macrophages in vitro — model for ITP, and orphan disease PRTX - 100 is not immunosuppressive like anti - TNFs ▪ Pretreat w dr
Slide 7: Efficacy trends from two phase I clinical studies in RA patients
Protalex , Inc. Efficacy trends from two phase I clinical studies in RA patients — US and So Africa PRTX - 100 - treated patients showed greater response than placebo - treated patients in all common measures of disease activity, including: ▪ ACR20/50/70 (American College of Rheumatology “patient
Slide 8: PRTX-100 Increases ACR50 Response in RA Patients on Background MTX Therapy
PRTX - 100 Increases ACR50 Response in RA Patients on Background MTX Therapy ACR50 Response Rate 0 5 10 15 20 25 30 35 0 29 57 85 PRTX - 100 + MTX Trial PRTX - 100 - 104: 41 patients w active RA randomized 3:1 Baseline MTX vs MTX + PRTX - 100, five weekly i.v . doses, 1.5, 3, 6, or 12 mcg/kg L
Slide 9: PRTX-100 treatment reduces CDAI<14 for three or more consecutive visits
Protalex , Inc. PRTX - 100 treatment reduces CDAI<14 for three or more consecutive visits 36% 31% 13% 0% 5% 10% 15% 20% 25% 30% 35% 40% MTX + PRTX-100 6 and 12 mcg/kg MTX + PRTX-100 All Doses MTX only Percent (%) 9
Slide 10: PRTX-100 effectively reduces measures of disease activity in RA patients
PRTX - 100 effectively reduces measures of disease activity in RA patients 0 5 10 15 20 25 30 PRTX-100 Placebo Patients with DAS28 score < 3.2 3/29 6/29 Trial PRTX - 100 - 103: 37 patients w active RA randomized 3:1 Baseline MTX vs PRTX - 100 + MTX, four weekly i.v . doses Last PRTX - 100 dose
Slide 11: DAS28 categorical analysis from US Ph I similar to APPEAL trial data (Enbrel)
Protalex , Inc. DAS28 categorical analysis from US Ph 1 similar to APPEAL trial data ( Enbrel ) 50% 50% 39% 0% 10% 20% 30% 40% 50% 60% Day 85 PRTX-100 Day 113 PRTX-100 Day 102 Enbrel APPEAL % with DAS28 < 3.2 MTX MTX + PRTX-100 (or Enbrel) 11
Slide 12: Competitive Advantage
PRTX - 100 Competitive Advantage Considerably lower cost production No immunosuppression / no “Black Box” Attractive safety profile allows for potential use in combination therapy Potentially applicable across a broad set of autoimmune diseases PRTX - 100 vs. current Biologicals 12 Protalex
Slide 13: Development Plans
PRTX - 100 Development Plans 13 2012 2013 2014 2015 2016 2017 PRTX - 100 Rheumatoid Arthritis PRTX - 100 Immune Thrombocytopenia Phase 1 So. Africa PRTX - 100 - 103 Phase 1 in USA PRTX - 100 - 104 Phase 2 Phase 3 Explore Partnership Preclinical Phase 1/2 Phase 3 Protalex , Inc.
Slide 14: Patents and Intellectual Property
Protalex , Inc. Patents and Intellectual Property Patents (five issued in US and one in Japan) ▪ Initial US patent 7,211,258, “Protein A compositions and methods of use” filed 2002 and issued 2007 for RA, juvenile RA, and systemic lupus erythematosus ▪ Continuation patents expanding use were issue
Slide 15: Key Team Members
Protalex , Inc. Protalex Key Team Members Arnold P Kling – President, Director; Principal of Niobe Ventures, LLC, experienced investor in and manager of early stage technology companies James W Dowe III – Vice - Chair of SAB; active investor in biotechnology, computer software and investment man
Slide 16: Milestones
Protalex , Inc. Protalex Milestones x 2Q13 Safety data from first three cohorts of PRTX - 100 - 104 x 3Q13 Initiation of cohort 5 extension study, to investigate monthly maintenance doses x 2Q14 Top - line results of PRTX - 100 - 104 trial □ 3Q14 Filing IND for PRTX - 100 in ITP □ 4Q14 Top - line re
Slide 17: Investment Thesis Summary
Protalex , Inc. Protalex Investment Thesis Summary PRTX - 100 – potentially a blockbuster drug ▪ Multiple clinical indications in both large and niche markets (RA, ITP) ▪ Potentially applicable across a broad set of autoimmune diseases ▪ Considerable cost advantage over competitors ▪ Preliminary r
Slide 18: September, 2014
September, 2014